Cargando…

Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease

OBJECTIVE: Psychiatric disorders have been implied as both risk factors and prodromal symptoms of Alzheimer's disease (AD). A better understanding of the history of psychiatric morbidity in people with AD may aid with understanding this relationship and highlight challenges in diagnosing AD in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alastalo, Aleksi, Tolppanen, Anna‐Maija, Nietola, Miika, Haapea, Marianne, Miettunen, Jouko, Hartikainen, Sirpa, Jääskeläinen, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311732/
https://www.ncbi.nlm.nih.gov/pubmed/35266140
http://dx.doi.org/10.1111/acps.13423
_version_ 1784753665380188160
author Alastalo, Aleksi
Tolppanen, Anna‐Maija
Nietola, Miika
Haapea, Marianne
Miettunen, Jouko
Hartikainen, Sirpa
Jääskeläinen, Erika
author_facet Alastalo, Aleksi
Tolppanen, Anna‐Maija
Nietola, Miika
Haapea, Marianne
Miettunen, Jouko
Hartikainen, Sirpa
Jääskeläinen, Erika
author_sort Alastalo, Aleksi
collection PubMed
description OBJECTIVE: Psychiatric disorders have been implied as both risk factors and prodromal symptoms of Alzheimer's disease (AD). A better understanding of the history of psychiatric morbidity in people with AD may aid with understanding this relationship and highlight challenges in diagnosing AD in people with concomitant psychiatric disorders. METHODS: Medication use and Alzheimer's disease (MEDALZ) study is a nationwide register‐based cohort of people (n = 70,718) who received a clinically verified AD diagnosis in Finland in 2005–2011 and were community‐dwelling at the time of diagnosis. The study population was divided into four groups based on psychiatric morbidity treated in specialized health care. We characterized the groups using data of psychiatric and somatic illnesses, psychotropic drug use, and socioeconomic factors and investigated factors associated with prodromal AD. RESULTS: Altogether, 4.3% of cohort members had a psychiatric diagnosis at least five years before AD diagnosis, 3.1% had a psychiatric diagnosis only up to five years before AD diagnosis, and 1.1% had a psychiatric diagnosis both less and more than 5 years before AD. Belonging to the Prodromal group (psychiatric diagnosis within 5 years before AD diagnosis) was most strongly associated with substance abuse (RR 65.06, 95%CI 55.54–76.22). Other associated factors with the Prodromal group were female gender, use of psychotropics, stroke, and asthma/COPD. CONCLUSION: Substance abuse and psychotropic drug use are common five years before AD diagnosis. These can be potential markers of possible prodromal symptoms of AD and should be acknowledged in clinical work.
format Online
Article
Text
id pubmed-9311732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93117322022-07-30 Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease Alastalo, Aleksi Tolppanen, Anna‐Maija Nietola, Miika Haapea, Marianne Miettunen, Jouko Hartikainen, Sirpa Jääskeläinen, Erika Acta Psychiatr Scand Original Articles OBJECTIVE: Psychiatric disorders have been implied as both risk factors and prodromal symptoms of Alzheimer's disease (AD). A better understanding of the history of psychiatric morbidity in people with AD may aid with understanding this relationship and highlight challenges in diagnosing AD in people with concomitant psychiatric disorders. METHODS: Medication use and Alzheimer's disease (MEDALZ) study is a nationwide register‐based cohort of people (n = 70,718) who received a clinically verified AD diagnosis in Finland in 2005–2011 and were community‐dwelling at the time of diagnosis. The study population was divided into four groups based on psychiatric morbidity treated in specialized health care. We characterized the groups using data of psychiatric and somatic illnesses, psychotropic drug use, and socioeconomic factors and investigated factors associated with prodromal AD. RESULTS: Altogether, 4.3% of cohort members had a psychiatric diagnosis at least five years before AD diagnosis, 3.1% had a psychiatric diagnosis only up to five years before AD diagnosis, and 1.1% had a psychiatric diagnosis both less and more than 5 years before AD. Belonging to the Prodromal group (psychiatric diagnosis within 5 years before AD diagnosis) was most strongly associated with substance abuse (RR 65.06, 95%CI 55.54–76.22). Other associated factors with the Prodromal group were female gender, use of psychotropics, stroke, and asthma/COPD. CONCLUSION: Substance abuse and psychotropic drug use are common five years before AD diagnosis. These can be potential markers of possible prodromal symptoms of AD and should be acknowledged in clinical work. John Wiley and Sons Inc. 2022-03-16 2022-05 /pmc/articles/PMC9311732/ /pubmed/35266140 http://dx.doi.org/10.1111/acps.13423 Text en © 2022 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Alastalo, Aleksi
Tolppanen, Anna‐Maija
Nietola, Miika
Haapea, Marianne
Miettunen, Jouko
Hartikainen, Sirpa
Jääskeläinen, Erika
Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease
title Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease
title_full Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease
title_fullStr Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease
title_full_unstemmed Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease
title_short Prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed Alzheimer's disease
title_sort prevalence and characteristics of psychiatric morbidity treated in specialized health care in a nationwide cohort of people with newly diagnosed alzheimer's disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311732/
https://www.ncbi.nlm.nih.gov/pubmed/35266140
http://dx.doi.org/10.1111/acps.13423
work_keys_str_mv AT alastaloaleksi prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease
AT tolppanenannamaija prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease
AT nietolamiika prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease
AT haapeamarianne prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease
AT miettunenjouko prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease
AT hartikainensirpa prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease
AT jaaskelainenerika prevalenceandcharacteristicsofpsychiatricmorbiditytreatedinspecializedhealthcareinanationwidecohortofpeoplewithnewlydiagnosedalzheimersdisease